• Bactolife raises EUR >30 million in Series B investment round
• Funding provides Bactolife with sufficient capital to commercialize its Binding Proteins and execution human study program
• Financing led by Cross Border Impact Ventures and EIFO (Danish Export and Investment Fund), and existing investors Novo Holdings and Athos
• Bactolife is expecting to launch its first Binding Protein products for Human Health in the US in 2026 and have plans to expand in Asia and EU in the years to follow.
• In addition to launch in the US, EU and Asia, Bactolife has an unwavering commitment to making Binding Proteins available for women and children in LMICs to ensure that our science-backed technology can be available for the many, not just the few

Copenhagen, Kingdom of Denmark – 06 January, 2026

Bactolife, a pioneering company in the field of gut health solutions, has successfully raised over EUR 30 million in its Series B investment round. The funding will enable the company to commercialize its innovation Binding Proteins, a new food, feed and dietary supplement ingredient, and execute its human study program, aimed at transforming human and animal health for proactive health management.

This significant financing round was led by Cross Border Impact Ventures (CBIV) and EIFO (Danish Export and Investment Fund), alongside continued support from existing investors Novo Holdings and Athos. With the backing of cornerstone investors, Bactolife is now poised to launch its first Binding Protein products under the ingredient brand, Helm™ for human health in the United States in 2026. The company plans to expand into Asia and Europe in the years that follow, with a strong commitment to ensuring the technology is accessible to women and children in low- and middle-income countries (LMICs).

Sebastian Søderberg, CEO of Bactolife, expressed his enthusiasm for the funding’s potential: “Today’s successful close of our Series B round sets the stage for exciting years ahead as we prepare to launch our innovative products in 2026. This funding will enable us to clinically validate, scale, and commercialize our Binding Proteins, taking Bactolife’s solutions to a broad audience. We are excited to welcome new investors to the Bactolife family and are deeply grateful to our existing investors, whose continued support reflects their confidence in our mission. We are ready to transform gut health with novel Binding Proteins.”

The proceeds from this round will be directed toward several key areas of growth for Bactolife, including the execution of its human study program across the US, EU, Asia, and LMICs. In addition, the company plans to scale its manufacturing and supply operations to meet global demand with a strong emphasis on commercialization of both human and animal health ingredients for dietary supplements, functional food and beverages, and feed additives.

Donna Parr, Managing Partner at Cross Border Impact Ventures, highlighted the broader impact of the investment: “We are thrilled to lead Bactolife’s Series B. Bactolife’s Binding Proteins have the potential to strengthen gut resilience for mothers and children in low- and middle-income countries by providing a scalable, food-grade solution that can be integrated into everyday nutrition. At the same time, we are excited about the significant growth opportunity across North America, Europe, and Asia where the market opportunity is massive. This investment reflects our conviction that evidence-based technologies can reach massive high-growth markets, inclusive of people who need them most, and we look forward to partnering with Bactolife to accelerate clinical validation, scale manufacturing, and expand equitable access globally.”

Bactolife’s Binding Proteins mark an important step forward in gut health solutions, providing a novel approach to supporting intestinal resilience by gently binding and neutralizing unhealthy metabolites. The company is committed to making its science-backed technology available for the many, not just the few, ensuring that individuals in both developed and developing regions have access to transformative healthcare solutions.

For further information, please contact:

Bactolife A/S
Julie Rastad, SVP
jlr@bactolife.com
+45 30770262

About Bactolife A/S

Bactolife is a biosolutions company pioneering a new era in proactive healthcare through our Binding Protein™ technology, a revolutionary category of functional proteins that neutralizes undesired metabolites and enhances gut resilience. ​

​Binding Proteins are discovered from natural camelid immunoglobins and upscaled through precision fermentation enabling stable and affordable supply. ​

​Our differentiated offering is well positioned in the fast-growing nutraceuticals space, meeting an un(der)served demand for innovation and capitalizing on strong consumer and customer desirability for scientifically proven specialty ingredients.​

Backed by our cornerstone investors Novo Holdings, Athos, CBIV, EIFO and the Gates Foundation, Bactolife is now ready for market entry in 2026.

About Binding Proteins

Binding Proteins are milk-inspired proteins developed to help maintain balance in the gastrointestinal system. These proteins are produced at scale using advanced biomanufacturing processes, ensuring they can be seamlessly incorporated into regular diets and feeds. By combining precision gut microbiome science with accessible food and feed product applications, Binding Proteins represent a transformative approach to gut health.

About Cross Border Impact Ventures (CBIV)
Cross Border Impact Ventures is a Canadian impact-driven investment firm focused on advancing breakthrough technologies with the potential to create large-scale positive social and environmental impact. CBIV invests in companies that can scale and deliver measurable results in improving the lives of underserved populations.

About EIFO (Danish Export and Investment Fund)
As Denmark’s national promotional bank and official export credit agency, EIFO works to open doors for global business, drive the green transition, advance innovative technologies, and contribute to Denmark’s security.

With total commitments exceeding EUR 22 billion and activities in more than 100 countries, EIFO provides financial solutions to Danish companies and their global partners.

EIFO is also Denmark’s largest venture investor, investing in both startups and funds. In 2024, EIFO made 78 investments in companies and 16 in funds.

About Novo Holdings A/S
Novo Holdings is a holding and investment company responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk

Foundation. Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk and Novonesis and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Planetary Health Investments and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development. As of year-end 2024, Novo Holdings had total assets of EUR 142 billion.

About ATHOS

With its heritage in healthcare and life sciences, ATHOS is a single-family office that supports entrepreneurs to positively impact health and well-being. Known to the broader public as the long-term majority investor of BioNTech, ATHOS remains committed to advancing medical innovation and building transformative companies for the future.